Navigation Links
Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City
Date:9/8/2010

at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: CompanyContact: Investor RelationsChristine BerniDonald C. Weinberger/Diana Bittner (media)Director of Investor RelationsWolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... Research and Markets  has announced the addition of the ... to their offering. The Central Nervous System ... segments of pharmaceuticals industry. The numbers of CNS disorders have ... unable to meet the market requirements. There has been steady ... over the past two decades. The market for CNS therapies ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... Data Reviewed in End of Phase 2a Meeting , ... (Nasdaq: VIAP ), a biotechnology company focused on ... metabolic disease, announced today that an end of Phase 2a ... held with the U.S. Food and Drug Administration (FDA). ...
... New Capabilities Will Further Extend GeneXpert System Technology Advantages , ... CPHD ) today announced that it has received a ... and Infectious Diseases to develop new ten-color detection technology for ... be awarded to Cepheid and the University of Medicine ...
Cached Medicine Technology:VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 2Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 3Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System 4
(Date:8/31/2014)... Sunday 31 August 2014: Mortality and morbidity ... year despite good use of oral anticoagulants, according to ... General Pilot Registry. The findings were presented for the ... chairperson Professor Gregory Lip (Birmingham, UK). , Professor Lip ... focused on management practices of European cardiologists conducted since ...
(Date:8/30/2014)... August 2014: A new batteryless cardiac pacemaker based ... motion was presented at ESC Congress 2014 today ... does not require battery replacement. , Mr Zurbuchen, ... at ARTORG, University of Bern, Switzerland, said: "Batteries ... Once they reach a critically low energy level, ...
(Date:8/30/2014)... In a world where a typical response to conflict is ... a game app to teach another way. Launched in ... is a colorful way to encourage moral values playfully. ... double-duty by teaching players new ways to find happiness and ... for consistently taking the high road, the Ultimate Karma game ...
(Date:8/30/2014)... August 31, 2014 Atlanta based automotive ... to help raise money and awareness for ALS by ... General Managers, staff, and even Vice President Jimmy Ellis ... film and can be viewed on their Youtube page; ... the challenge, general managers and staff also took the ...
(Date:8/30/2014)... 30, 2014 The Truth about Six Pack ... will reveal to users some shocking foods that can burn ... in modeling looks, as well as some motivation secrets for ... that there is one unique trick that can help users ... despite what many people might think, cardio exercise routines are ...
Breaking Medicine News(10 mins):Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2Health News:Newly Launched Ultimate Karma App Elicits Happiness in Players and Encourages Moral Values 2Health News:Jim Ellis Automotive Group Take the ALS Ice Bucket Challenge 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2
... age, they,often become forgetful and unsteady and may have ... need help recovering from an,injury or illness. Many don,t ... the familiar surroundings of home. The dilemma children,then face ... cared for without,placing them in an assisted living facility. ...
... to Play a Key Role as Governments and Civil Society ... Region Ponder Urgent Strategies to Tackle the Crisis, ... -- On World AIDS Day 2007, hundreds, perhaps thousands, of ... HIV in cities across,the Asia Pacific, becoming the latest statistics ...
... hip arthroplasty (THA), or hip replacement, is an ... have only followed patients for up to one ... issue of Arthritis Care & Research ( http://www.interscience.wiley.com/journal/arthritiscare ... years following hip replacement and found a long-term ...
... SAN FRANCISCO, Nov. 28 ECO2 Plastics, Inc.,(OTC ... eco-friendly,recycling company that is changing the way plastics ... that the Company,s,proprietary cleaning process can produce PET ... the manufacturing of food-contact containers., "Based upon ...
... Conseco, Inc. (NYSE:,CNO) said today that it has agreed to ... Group, Inc. (LTCG) for certain,back-office functions of the long term ... earlier this year that it was,considering this solution. Under the ... the customer call center and the ...
... -- There are estimated to be between ... with chronic Immune Thrombocytopenic Purpura (ITP), an autoimmune ... in their blood -- causing bruises, nosebleeds and, ... an international multicenter clinical research study led by ...
Cached Medicine News:Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 2Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 4Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 5Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 6Health News:Long-term improvement seen with hip replacement 2Health News:ECO2 Plastics to File for FDA Approval for Food-Contact Applications 2Health News:ECO2 Plastics to File for FDA Approval for Food-Contact Applications 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Hoffmann® II Hybrid External Fixation System ... generation in hybrid fixation. It incorporates ... and is designed to offer speed ... patented Hoffmann® snap-fit technology. , ,Using ...
Medicine Products: